An Extension Study to Evaluate the Long-Term Safety of QGE031 in Chronic Spontaneous Urticaria Patients from a Previous Study

Overview

Información sobre este estudio

The purpose of this extension study is to evaluate the long-term safety of QGE031 when given to patients with chronic spontaneous urticaria who completed the previous study CQGE031C2201.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • To be eligible for inclusion in this study all of the following criteria must be fulfiled
    • Written informed consent must be obtained before any assessment is performed
    • Patients who complete the treatment epoch in study CQGE031C2201 and complete at least visit 203 (Week 32 of the follow-up epoch, ≥16 weeks after last injection) and present with active disease as defined by UAS7 ≥12
    • Patients must not have any missing eDiary entries in the 7 days prior to visit 301 (patients are allowed to repeat until this criterion is met)
    • Willing and able to complete a daily symptom eDiary for the duration of the study and adhere to the study visit schedules

Exclusion Criteria:

  • Clearly defined underlying etiology for chronic urticaria other than chronic spontaneous urticaria 
  • Evidence of parasitic infection 
  • Any other skin diseases than chronic spontaneous urticaria with chronic itching 
  • Contraindications to or hypersensitivity to fexofenadine, loratadine, cetirizine, or epinephrine 
  • History of anaphylaxis 
  • History or current diagnosis of ECG abnormalities indicating significant risk of safety for patients participating in the study
  • History of hypersensitivity to any of the study drugs or its components of similar chemical classes 
  • Pregnant or nursing (lactating) women
  • Other protocol-defined inclusion/exclusion criteria may apply

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Rochester, Minn.

Investigador principal de Mayo Clinic

Gerald Volcheck, M.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available
.
CLS-20256938

Mayo Clinic Footer